On ECHEMI
Home > Drugs > Sunflower Pharmaceutical Group (Jizhou) Co., Ltd.
Sunflower Pharmaceutical Group (Jizhou) Co., Ltd.
  • Founded in:

    2001-04-27
  • Country:

    China China
  • Address:

    No. 588, Yongxing West Road, Jizhou District, Hengshui City
  • Tax NO.:

    91131181601682772X
  • Registered Funds:

    76.08 million yuan
  • Website:

  • Email:

Related Drugs
Compound sulfamethoxazole injection
Trimethoprim, sulfamethoxazole.
Name Description Content CAS NO. Registered Holders
Trimethoprim

It acts on the second step of folic acid anabolism and selectively inhibits the action of dihydrofolate reductase. When used in combination with sulfamethoxazole, it can double-block the bacterial folic acid metabolism and enhance the synergistic antibacterial effect.

More

It acts on the second step of folic acid anabolism and selectively inhibits the action of dihydrofolate reductase. When used in combination with sulfamethoxazole, it can double-block the bacterial folic acid metabolism and enhance the synergistic antibacterial effect.

738-70-5 44
Sulfamethoxazole

It acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis. When used in combination with trimethoprim, it can double-block the bacterial folic acid metabolism and enhance the synergistic antibacterial effect, especially for Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus. The antibacterial effect is significantly enhanced compared with a single drug.

More

It acts on dihydrofolate synthase, interfering with the first step of folic acid synthesis. When used in combination with trimethoprim, it can double-block the bacterial folic acid metabolism and enhance the synergistic antibacterial effect, especially for Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus. The antibacterial effect is significantly enhanced compared with a single drug.

723-46-6 33
Cytochrome C Injection
This product is a sterile aqueous solution of cytochrome C
Name Description Content CAS NO. Registered Holders
Cytochrome C

A protein with iron porphyrin as a cofactor existing in the mitochondria of cells, arranged in a certain order to form a cytochrome system. The Fe3 in its molecules can undergo a reversible redox reaction under the action of related enzymes, and is responsible for the transfer of electrons, which is indispensable for cell respiration. When tissues are hypoxic, exogenous agents can enter the cells and play a role in correcting cell respiration and material metabolism.

More

A protein with iron porphyrin as a cofactor existing in the mitochondria of cells, arranged in a certain order to form a cytochrome system. The Fe3 in its molecules can undergo a reversible redox reaction under the action of related enzymes, and is responsible for the transfer of electrons, which is indispensable for cell respiration. When tissues are hypoxic, exogenous agents can enter the cells and play a role in correcting cell respiration and material metabolism.

9007-43-6 0
Lomefloxacin Aspartate Injection
The main ingredient of this product is lomefloxacin aspartate, and its chemical name is: 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid aspartate
Name Description Content CAS NO. Registered Holders
LOMEFLOXACIN, ASPARTATE

Lomeza is a broad-spectrum quinolone antibiotic that has bactericidal effects on Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. It has good antibacterial effects on methicillin-resistant Staphylococcus aureus, ampicillin-resistant influenza bacilli, pipemidic acid-resistant Escherichia coli and bacteria resistant to other drugs. Its antibacterial mechanism is to inhibit the activity of bacterial DNA helicase, thereby inhibiting bacterial DNA transcription and replication, and has bactericidal effects on a variety of Gram-positive and Gram-negative bacteria.

More

Lomeza is a broad-spectrum quinolone antibiotic that has bactericidal effects on Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. It has good antibacterial effects on methicillin-resistant Staphylococcus aureus, ampicillin-resistant influenza bacilli, pipemidic acid-resistant Escherichia coli and bacteria resistant to other drugs. Its antibacterial mechanism is to inhibit the activity of bacterial DNA helicase, thereby inhibiting bacterial DNA transcription and replication, and has bactericidal effects on a variety of Gram-positive and Gram-negative bacteria.

211690-33-4 7
Furosemide Injection
The main ingredient of this product: furosemide. Chemical name: 2-[(2-furanmethyl)amino]-5-(aminosulfonyl)-4-chlorobenzoic acid. Molecular formula: C12H11ClN2O5S Molecular weight: 330.75 Excipients: sodium chloride, sodium hydroxide, water for injection
Name Description Content CAS NO. Registered Holders
Furosemide

1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc., inhibit the active reabsorption of NaCl by the thick-walled segment of the renal tubular loop, reduce the reabsorption of Na+ and Cl-, and promote the secretion of K+ by the distal tubule; 2. Effect on hemodynamics: It increases the content of prostaglandin E2 by inhibiting the activity of prostaglandin degrading enzymes, dilates blood vessels, reduces renal vascular resistance, and increases renal blood flow; it is helpful in the treatment of acute left heart failure and adult respiratory distress syndrome.

More

1. Effect on water and electrolyte excretion: It can increase the excretion of water, sodium, chloride, potassium, calcium, magnesium, phosphorus, etc., inhibit the active reabsorption of NaCl by the thick-walled segment of the renal tubular loop, reduce the reabsorption of Na+ and Cl-, and promote the secretion of K+ by the distal tubule; 2. Effect on hemodynamics: It increases the content of prostaglandin E2 by inhibiting the activity of prostaglandin degrading enzymes, dilates blood vessels, reduces renal vascular resistance, and increases renal blood flow; it is helpful in the treatment of acute left heart failure and adult respiratory distress syndrome.

54-31-9 48
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.